



Omply Patent Application (00002534)

Omply Health Oy has filed a patent application covering a new remote diagnostics operating model and a data-driven technical solution. The application has been submitted to the Finnish Patent and Registration Office and establishes a priority date for Omply, enabling future expansion of the protection to international systems (WIPO, EPO, USPTO, GCC patent offices).

The patenting process proceeds in the same manner regardless of industry. The authority evaluates the application for 12–18 months, and during this period the contents of the application are not public. This is not due to any company-specific decision, but is required by international patent law. Both the European Patent Office and the World Intellectual Property Organization (WIPO) advise that the contents of an application must not be disclosed prior to official publication. The application becomes publicly available only when the authority releases it into public databases (such as Espacenet or WIPO PatentScope).

Because Omply’s application contains core company technology, premature disclosure could weaken the scope of protection or expose the solution to copying. This risk has been highlighted in several international cases in which a company’s own early disclosure has become a so-called “self-collision” prior art publication and diminished the resulting patent protection. The practical guideline is therefore that the contents of a patent application must not be shared publicly before the authority’s official publication.

Omply’s patent seeks protection for a technical operating model designed to improve the accuracy of remote diagnostics and enable device-agnostic data utilisation. Such models typically represent a company’s strongest competitive advantage. Similar practices are seen across the health and technology sectors, where companies working on telehealth or sensor innovations delay broader disclosure until the patent office has made the application public. Well-known examples include several telehealth and sensor-technology companies that reveal technical details only after official publication.

Once the patent authority later publishes Omply’s application, we will be able to share its contents and implications more openly. At this stage, the priority is to ensure that the protection process proceeds in a controlled manner and that the patent’s full value is secured. Omply will communicate the progress of the patenting process step by step and provide greater transparency as soon as the authority has released the documents. This approach ensures both the protection of the technology and the interests of our investors.

Chief Executive Officer Tatu Lintukangas, Omply Health Oy